Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
A 59-year-old man with a high level of antinuclear antibody received nivolumab and ipilimumab plus chemotherapy for lung cancer. Two weeks after the second course, he was admitted with a fever and severe fatigue. Laboratory studies showed elevated markers of myocardial damage, and a myocardial biopsy showed inflammatory cell infiltration, damaged myocardial fibers. Myocarditis was diagnosed as an immune-related adverse event (irAE), and high-dose corticosteroids were initiated. However, his cardiac function rapidly worsened, and he died on the fifth day after admission. There is no established treatment strategy for fulminant myocarditis as an irAE, and the further exploration of viable treatment strategies is required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 62(2023), 9 vom: 01. Mai, Seite 1319-1322 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nishimura, Tomoka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 02.05.2023 Date Revised 26.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.0505-22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346473144 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346473144 | ||
| 003 | DE-627 | ||
| 005 | 20231226031537.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.0505-22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346473144 | ||
| 035 | |a (NLM)36130891 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nishimura, Tomoka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2023 | ||
| 500 | |a Date Revised 26.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 59-year-old man with a high level of antinuclear antibody received nivolumab and ipilimumab plus chemotherapy for lung cancer. Two weeks after the second course, he was admitted with a fever and severe fatigue. Laboratory studies showed elevated markers of myocardial damage, and a myocardial biopsy showed inflammatory cell infiltration, damaged myocardial fibers. Myocarditis was diagnosed as an immune-related adverse event (irAE), and high-dose corticosteroids were initiated. However, his cardiac function rapidly worsened, and he died on the fifth day after admission. There is no established treatment strategy for fulminant myocarditis as an irAE, and the further exploration of viable treatment strategies is required | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a case report | |
| 650 | 4 | |a irAE | |
| 650 | 4 | |a myocarditis | |
| 650 | 4 | |a nivolumab plus ipilimumab | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 700 | 1 | |a Ninomiya, Kiichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakashima, Mitsutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Akagi, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kuribayashi, Tadahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Higo, Hisao |e verfasserin |4 aut | |
| 700 | 1 | |a Hotta, Katsuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Yoshinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kiura, Katsuyuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 62(2023), 9 vom: 01. Mai, Seite 1319-1322 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:9 |g day:01 |g month:05 |g pages:1319-1322 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.0505-22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 9 |b 01 |c 05 |h 1319-1322 | ||